Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Ambulatory outpatients with breast (including ductal carcinoma in situ \[DCIS\]) cancer.~2. Patients to be treated with RT for curative intent.~3. Women ≥18 years of age.~4. Eastern Cooperative Oncology Group (ECOG) performance status \<3 (Appendix 4).~5. Hemoglobin ≥ 9 g/dL~6. Either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control during study treatment and for 3 months afterwards.~7. Subjects who are currently taking melatonin must discontinue melatonin for 5 days before enrolling in the study.~8. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria~1. Fatigue brought on by conditions other than cancer such as (the indicated tests are required only if that mechanism of fatigue is suspected):~   * uncontrolled hypothyroidism (TSH \>10 IU)~  * hypercalcemia (calcium \>11 mg/dL) Calcium (Ca) = Serum Calcium (SerumCa) + 0.8 \* (NormalAlbumin - PatientAlbumin)~  * decompensated congestive heart failure~  * chronic obstructive pulmonary disease requiring oxygen replacement~2. Patients with a creatinine clearance \<30 mL/min~3. Aspartate aminotransferase (AST) \> 3X upper limit of normal (ULN)~4. Alanine aminotransferase (ALT) \> 3X ULN~5. Bilirubin \> 1X ULN~6. Use of systemic steroids, or other pharmacological agents such as methylphenidate for cancer-related fatigue~7. Current use of American ginseng, remelteon, or warfarin.~8. Depression ≥ grade 2 (CTCAE v4.0)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg Melatonin (Type: ACTIVE_COMPARATOR): RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
- Placebo (Type: PLACEBO_COMPARATOR): RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).

Based on this trial design, predict the completion outcome and termination type (if applicable).